Structure and function in gene patenting

Nature Genetics

Volumn 15, Issue 2, 1997, Pages 125-130

  Eisenberg, Rebecca S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CELL SURFACE RECEPTOR; DNA; LEPTIN RECEPTOR; SYNTHETIC DNA;

ANIMAL; CHEMISTRY; DRUG INDUSTRY; EUROPE; GENE; GENETICS; HUMAN; LEGAL ASPECT; MOUSE; PATENT; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION; UNITED STATES;

ANIMALS; CARRIER PROTEINS; DNA; DRUG INDUSTRY; EUROPE; GENES; GENES, SYNTHETIC; HUMANS; INTELLECTUAL PROPERTY; MICE; PATENTS; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES;

EID: 0031067987     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0297-125     Document Type: Note

References (66)

1. Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200 (Fed. Cir.), cert denied sub nom. Genetics Institute v. Amgen, 502 U.S. 856 (1991).
2. In re Papesch. 315F.2d 381 (CCPA 1963).
3. U.S. Patent Act, 35 U.S. Code § 103(a).
4. Final act embodying the results of the Uruguay round of multilateral trade negotiations, Apr. 15, 1994, Annex IC Agreement on Trade-Related Aspects of Intellectual Property Rights §5 27-34, 33I.L.M.81. reprinted in The Results of the Uruguay Round of Multilateral Trade Negotiations—The Legal Texts (ed.
5. GATT Secretariat) 1-19, 365-403 (1994).
6. Convention on the Grant of European Patents § 53, opened for signature October 5, 13 I.L.M. 290 (1973).
7. Dickson, D. Europe tries to untangle laws on patenting life. Science 243 1002-1003 (1989).
8. Kass, L.R. Patenting Life. Commentary at p.56. (December, 1981).
9. Dresser, R. Ethical and legal issues in patenting new animal life. Jurimet J. 28 399-435 (1988).
10. U.S Code§ 101.
11. U.S. Code §102.
12. U.S. Code §§101, 112.
13. U.S. Code §103.
14. U.S.Code§112.
15. Funk Bros. Seed Co. v. Kalo Inoculant Co., 33 U.S. 127 (1948).
16. Amgen Inc. v. Chugai Pharmaceutical Co., 13 USPQ2d (BNA) 1737, 1759 (D. Mass. 1989).
17. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
18. Parke-Davis & Co. v. H.K. MuHord & Co. 189 F. 95 (S.D.N.Y. 1911).
19. Kuehmsted v. Farbenfabriken. 179 F. 701 (7th Or. 1910), cert denied. 220 U.S. 622 (1911).
20. Merck & Co. v. Olin Mathieson Corp 253 F.2d 156 (4th Cir. 1958).
21. In re Bergstrom, 427 F.2d 1394 (CC.PA. 1970).
22. In re Deuel. 51 F.3d 1552 (Fed. Cir. 1995).
23. In re Bell. 991 F.2d 781 (Fed. Cir. 1993).
24. Brenner v. Manson, 383 U.S. 519 (1966).
25. Eisenberg, R. & Merges, R. Opinion letter as to the patentability of certain inventions associated with the identification of partial cDNA sequences. Amer. Intell. Prop. L. Ass'n Q. J. 23, 1-52 (1995).
26. U.S. Pat & Trademark Off. PTO Utility examination guidelines Fed. Reg. 60, 36, 263 (1995).
27. In re Spada. 911 F.2d 705 (Fed. Cir. 1990).
28. In re Thuau, 135 F.2d 344 (CCPA 1943).
29. In re May. 574 F.2d 1082 (CCPA 1978).
30. U.S. Patent No. 4,724,232 (Feb. 9, 1988).
31. U.S. Patent No. 4,833,130 (May 23, 1989).
32. U.S. Patent No. 4,837,208 (June 6, 1989).
33. U.S. Patent No. 4,818,750 (Apr. 4, 1989).
34. U.S. Patent No. 4,828.838 (May 9, 1989).
35. U.S. Patent No. 4,818,538 (Apr. 4, 1989).
36. Ex parte Novitski. 26 USPQ2d (BNA) 1389 (Bd. Pat App. & Interf. 1993).
37. In re Hoch, 428F.2d 1341 (1970).
38. F.2d 688 (Fed. Cir. 1990). cert denied sub nom. Dillon v. Manbeck, 500 U.S. 904 (1991).
39. F.2d 81,195 USPQ (BNA) 753 (CCPA 1977).
40. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-431 (1994).
41. Hamilton, J. et al. Is this 'fat gene' worth its fat tab? Business Week (March 20, 1995).
42. Lönnqvist, F., Amer, P., Norfors, L. & Schalling, M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Mature Med. 1, 950-953 (1995).
43. Hamilton, B.S., Paglia, D., Kwan, A.T.M. & Dertel, M. Increased obese mRNA expression in developmental fat cells from massively obese humans. Nature Med. 1, 953-956 (1995).
44. Maffei, M. et al. Leptin levels in human and rodent: measurement of plasma leptin and OB RNA in obese and weight reduced subjects. Nature Med. 1. 1155-1161 (1995).
45. Considine, R.V. et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl. J. Med. 334, 292-295 (1996).
46. Tartaglia, L.A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-71 (1995).
47. Millennium Pharmaceuticals, Inc., Common Stock Prospectus at p.11 (May 6, 1996).
48. Progenitor, Inc., Progenitor announces publication of patent application for leptin receptor (Press Release. March 22, 1996).
49. Patent Cooperation Treaty June 19, 1970, 28U.S.T.7645. as amended, Art. 21.
50. Progenitor, Inc., International Patent Application No. WO 96/08510 (March, 21 1996).
51. Cioffi, J.A. et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nature Med. 2, 585-589 (1996).
52. Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor identification of a mutation in the leptin receptor gene in dbldb mice. Cell 84, 491-495 (1996).
53. Lee, G.H. et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632-635 (1996).
54. Vaisse, C. et al. Leptin activation of Stat3 in the hypothalamus of wild-type and oblob mice but not dbldb mice. Nature Genet 14, 85-96 (1996).
55. Progenitor, Inc., Common stock prospectus (subject to completion, dated July 11, 1996)
56. Reuters Financial Service. Progenitor Inc. postpones IPO, cites market (Aug. 30, 1996) (available in LEXIS, News Library, Wires File).
57. Business Wire. Amgen and Progenitor sign leptin receptor agreement (Jan. 6, 1997) (available in LEXIS, News Library, Wires File).
58. Sherwood, P. Owning genes vs. cloning genes. Bioventure View 15-16 (June, 1996).
59. F.3d 1555(1994).
60. Greer, T.J. Jr. Writing and Understanding U.S. Patent Claims (Michie, Charlottesville, VA. 1979).
61. U.S. Pat No. 5,506,133 (Apr. 9, 1996).
62. U.S. Pat No. 5,504,003 (Apr. 2, 1996).
63. U.S. Pat No. 5,501,969 (Mar. 26, 1996).
64. Goldstein, J. & McConathy, E. Patent applications on partial cDNA sequences. J. NIH Res. 7, 58-61 (1995).
65. Steffe, E. & Covert, J. Expressed sequence tags: any prior art effect? Biotechnol. Law Report 14, 947-952 (1995).
66. In re Hack, 245 F.2d 246, 248 (CCPA 1957).